Multiple mechanisms and applications of tertiary lymphoid structures and immune checkpoint blockade

被引：0
作者：
Li, Zelin [1 ]
Liu, Shuhan [1 ]
Liu, Deyu [2 ]
Yang, Kangping [3 ]
Xiong, Jing [1 ,4 ]
Fang, Ziling [1 ,5 ]
机构：
[1] Nanchang Univ, Affiliated Hosp 1, Jiangxi Med Coll, Nanchang, Peoples R China
[2] Nanchang Univ, Jiangxi Med Coll, Queen Mary Sch, Dept Clin Med, Nanchang, Peoples R China
[3] Nanchang Univ, Affiliated Hosp 2, Jiangxi Med Coll, Nanchang, Peoples R China
[4] Nanchang Univ, Affiliated Hosp 1, Jiangxi Med Coll, Dept Gen Practice, Nanchang, Peoples R China
[5] Nanchang Univ, Affiliated Hosp 1, Jiangxi Med Coll, Dept Oncol, Nanchang, Peoples R China
来源：
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH | 2025年 / 44卷 / 01期
关键词：
Immune checkpoint blockade; Immune escape; Tertiary lymphoid structures; Immune-related adverse events; Immunotherapy; Cancer; T-CELL INFILTRATION; ACQUIRED-RESISTANCE; B-CELLS; IMMUNOTHERAPY RESPONSE; CTLA-4; BLOCKADE; PLASMA-CELLS; INHIBITORS; SURVIVAL; OUTCOMES; CD8(+);
D O I：
10.1186/s13046-025-03318-6
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
BackgroundImmune checkpoint blockade (ICB) inhibits tumor immune escape and has significantly advanced tumor therapy. However, ICB benefits only a minority of patients treated and may lead to many immune-related adverse events. Therefore, identifying factors that can predict treatment outcomes, enhance synergy with ICB, and mitigate immune-related adverse events is urgently needed.Main textTertiary lymphoid structures (TLS) are ectopic lymphoid tissues that arise from the tumor periphery. They have been found to be associated with better prognosis and improved clinical outcomes after ICB therapy. TLS may help address the problems associated with ICB. The multiple mechanisms of action between TLS and ICB remain unknown. This paper described potential mechanisms of interaction between the two and explored their potential applications.
引用
收藏
页数：17
相关论文
共 114 条
  • [1] Liu D., Et al., Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma, Nat Med, 25, 12, pp. 1916-1927, (2019)
  • [2] Doroshow D.B., Et al., Immunotherapy in Non-small Cell Lung Cancer: facts and hopes, Clin Cancer Res, 25, 15, pp. 4592-4602, (2019)
  • [3] Zhang Y., Et al., A case report of advanced thymoma re-treated with PD-1 inhibitor after initial immune-related pneumonitis, Ann Palliat Med, 10, 9, pp. 10083-10090, (2021)
  • [4] Chen Y., Et al., An Immune-Related Gene Prognostic Index for Head and Neck squamous cell carcinoma, Clin Cancer Res, 27, 1, pp. 330-341, (2021)
  • [5] Weng J., Et al., Exploring immunotherapy in colorectal cancer, J Hematol Oncol, 15, 1, (2022)
  • [6] Petitprez F., Et al., The Tumor Microenvironment in the response to Immune Checkpoint Blockade therapies, Front Immunol, 11, (2020)
  • [7] Schoenfeld A.J., Hellmann M.D., Acquired Resistance to Immune Checkpoint inhibitors, Cancer Cell, 37, 4, pp. 443-455, (2020)
  • [8] Baxi S., Et al., Immune-related adverse events for anti-PD-1 and anti-PD-L1 drugs: systematic review and meta-analysis, BMJ, 360, (2018)
  • [9] Sibaud V., Dermatologic reactions to Immune Checkpoint inhibitors: skin toxicities and immunotherapy, Am J Clin Dermatol, 19, 3, pp. 345-361, (2018)
  • [10] Sangro B., Et al., Diagnosis and management of toxicities of immune checkpoint inhibitors in hepatocellular carcinoma, J Hepatol, 72, 2, pp. 320-341, (2020)
12345678910